409 related articles for article (PubMed ID: 33319692)
1. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
[TBL] [Abstract][Full Text] [Related]
2. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
Liu G; Wang W; Wan Y; Ju X; Gu S
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
[TBL] [Abstract][Full Text] [Related]
3. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
[TBL] [Abstract][Full Text] [Related]
4. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
5. An
da Costa APL; Cardoso FJB; Molfetta FA
J Biomol Struct Dyn; 2023 Mar; 41(5):1715-1729. PubMed ID: 34996334
[TBL] [Abstract][Full Text] [Related]
6. What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
Paneth A; Płonka W; Paneth P
J Mol Model; 2017 Oct; 23(11):317. PubMed ID: 29046967
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
Lee YH; Yi GS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
9. Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.
Annan A; Raiss N; Lemrabet S; Elomari N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
Int J Immunopathol Pharmacol; 2024; 38():3946320241231465. PubMed ID: 38296818
[TBL] [Abstract][Full Text] [Related]
10. QSAR and Pharmacophore Mapping Studies on Benzothiazinimines to Relate their Structural Features with anti-HIV Activity.
Geethaavacini G; Poh GP; Yan LY; Deepashini R; Shalini S; Harish R; Sureshkumar K; Ravichandran V
Med Chem; 2018; 14(7):733-740. PubMed ID: 29807521
[TBL] [Abstract][Full Text] [Related]
11. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
Cele FN; Ramesh M; Soliman ME
Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
[TBL] [Abstract][Full Text] [Related]
12. Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties.
Zhang Y; Chen L; Wang Z; Zhu Y; Jiang H; Xu J; Xiong F
J Biomol Struct Dyn; 2024 May; 42(8):4196-4213. PubMed ID: 37272892
[TBL] [Abstract][Full Text] [Related]
13. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
14. Docking field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.
Fan N; Zhang S; Sheng T; Zhao L; Liu Z; Liu J; Wang X
Chem Biol Drug Des; 2018 Feb; 91(2):398-407. PubMed ID: 28816417
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR, molecular docking, and molecular dynamics simulation of a novel thieno[3,4-d]pyrimidine inhibitor targeting human immunodeficiency virus type 1 reverse transcriptase.
Chu H; He QX; Wang JW; Deng YT; Wang J; Hu Y; Wang YQ; Lin ZH
J Biomol Struct Dyn; 2020 Sep; 38(15):4567-4578. PubMed ID: 31760877
[TBL] [Abstract][Full Text] [Related]
16. Revolutionizing antiretroviral therapy for human immunodeficiency virus/AIDS: A computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates.
Annan A; Raiss N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
Int J Immunopathol Pharmacol; 2023; 37():3946320231207514. PubMed ID: 37850462
[TBL] [Abstract][Full Text] [Related]
17. Designing hypothesis of substituted benzoxazinones as HIV-1 reverse transcriptase inhibitors: QSAR approach.
Veerasamy R; Subramaniam DK; Chean OC; Ying NM
J Enzyme Inhib Med Chem; 2012 Oct; 27(5):693-707. PubMed ID: 21961709
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads.
Vadivelan S; Deeksha TN; Arun S; Machiraju PK; Gundla R; Sinha BN; Jagarlapudi SA
Eur J Med Chem; 2011 Mar; 46(3):851-9. PubMed ID: 21272964
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic insights into mode of action of novel natural cathepsin L inhibitors.
Tyagi C; Grover S; Dhanjal J; Goyal S; Goyal M; Grover A
BMC Genomics; 2013; 14 Suppl 8(Suppl 8):S10. PubMed ID: 24564425
[TBL] [Abstract][Full Text] [Related]
20. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
